Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.

Nolan T, Booy R, Marshall HS, Richmond P, Nissen M, Ziegler JB, Baine Y, Traskine M, Jastorff A, Van der Wielen M.

Pediatr Infect Dis J. 2019 Jun;38(6):643-650. doi: 10.1097/INF.0000000000002334.

PMID:
31116180
3.

Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine.

Knuf M, Helm K, Kolhe D, Van Der Wielen M, Baine Y.

Vaccine. 2018 May 31;36(23):3286-3295. doi: 10.1016/j.vaccine.2018.04.064. Epub 2018 Apr 30.

4.

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial.

Merino Arribas JM, Carmona Martínez A, Horn M, Perez Porcuna XM, Otero Reigada MDC, Marès Bermúdez J, Centeno Malfaz F, Miranda M, Mendez M, Garcia Cabezas MA, Christoph W, Bleckmann G, Fischbach T, Kolhe D, Van der Wielen M, Baine Y.

Pediatr Infect Dis J. 2018 Jul;37(7):704-714. doi: 10.1097/INF.0000000000002061.

PMID:
29620722
5.

Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.

Klein NP, Abu-Elyazeed R, Cornish M, Leonardi ML, Weiner LB, Silas PE, Grogg SE, Varman M, Frenck RW, Cheuvart B, Baine Y, Miller JM, Leyssen M, Mesaros N, Roy-Ghanta S.

Vaccine. 2017 Jun 16;35(28):3564-3574. doi: 10.1016/j.vaccine.2017.05.018. Epub 2017 May 20.

6.

Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.

Merino Arribas JM, Carmona Martínez A, Horn M, Perez Porcuna XM, Otero Reigada MD, Marès Bermúdez J, Centeno Malfaz F, Miranda M, Mendez M, Garcia Cabezas MA, Wittermann C, Bleckmann G, Fischbach T, Kolhe D, van der Wielen M, Baine Y.

Pediatr Infect Dis J. 2017 Apr;36(4):e98-e107. doi: 10.1097/INF.0000000000001484.

PMID:
28002359
7.
8.

Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children.

Klein NP, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M.

Pediatr Infect Dis J. 2016 Jun;35(6):662-72. doi: 10.1097/INF.0000000000001123.

PMID:
26928521
9.

Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.

Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M.

Pediatr Infect Dis J. 2015 Nov;34(11):1236-43. doi: 10.1097/INF.0000000000000866.

PMID:
26237742
10.

Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.

Leonardi M, Latiolais T, Sarpong K, Simon M, Twiggs J, Lei P, Rinderknecht S, Blatter M, Bianco V, Baine Y, Friedland LR, Baccarini C, Miller JM.

Vaccine. 2015 Feb 11;33(7):924-32. doi: 10.1016/j.vaccine.2014.09.064. Epub 2014 Oct 8.

11.

Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.

Leonardi M, Latiolais T, Sarpong K, Simon M, Twiggs J, Lei P, Rinderknecht S, Blatter M, Bianco V, Baine Y, Friedland LR, Miller JM.

Vaccine. 2015 Feb 11;33(7):933-41. doi: 10.1016/j.vaccine.2014.08.027. Epub 2014 Aug 21.

12.

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age.

Halperin SA, Baine Y, Domachowske JB, Aggarwal N, Simon M, Langley JM, McNeil SA, Friedland LR, Bianco V, Baccarini CI, Miller JM.

J Pediatric Infect Dis Soc. 2014 Mar;3(1):33-42. doi: 10.1093/jpids/pit058. Epub 2013 Oct 17.

13.

Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.

Lupisan S, Limkittikul K, Sosa N, Chanthavanich P, Bianco V, Baine Y, Van der Wielen M, Miller JM.

Clin Vaccine Immunol. 2013 Oct;20(10):1499-507. doi: 10.1128/CVI.00162-13. Epub 2013 Jul 24.

14.

One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children.

Klein NP, Baine Y, Bianco V, Lestrate PR, Naz A, Blatter M, Friedland LR, Miller JM.

Pediatr Infect Dis J. 2013 Jul;32(7):760-7. doi: 10.1097/INF.0b013e31828693c5.

PMID:
23348814
15.

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.

Knuf M, Romain O, Kindler K, Walther U, Tran PM, Pankow-Culot H, Fischbach T, Kieninger-Baum D, Bianco V, Baine Y, Miller J.

Eur J Pediatr. 2013 May;172(5):601-12. doi: 10.1007/s00431-012-1924-0. Epub 2013 Jan 11.

16.
17.

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.

Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM.

Hum Vaccin Immunother. 2012 Jul;8(7):866-72. doi: 10.4161/hv.20229. Epub 2012 Apr 9.

18.

The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults.

Aplasca-De Los Reyes MR, Dimaano E, Macalalad N, Dbaibo G, Bianco V, Baine Y, Miller J.

Hum Vaccin Immunother. 2012 Jul;8(7):881-7. doi: 10.4161/hv.20212. Epub 2012 Apr 9.

19.

A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial.

Østergaard L, Silfverdal SA, Berglund J, Flodmark CE, West C, Bianco V, Baine Y, Miller JM.

Vaccine. 2012 Jan 17;30(4):774-83. doi: 10.1016/j.vaccine.2011.11.051. Epub 2011 Nov 19.

PMID:
22107850
20.

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

Miller JM, Mesaros N, Van Der Wielen M, Baine Y.

Adv Prev Med. 2011;2011:846756. doi: 10.4061/2011/846756. Epub 2011 Jul 18.

21.

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults.

Bermal N, Huang LM, Dubey AP, Jain H, Bavdekar A, Lin TY, Bianco V, Baine Y, Miller JM.

Hum Vaccin. 2011 Feb;7(2):239-47. Epub 2011 Feb 1.

PMID:
21343698
22.

Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.

Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM.

Pediatr Infect Dis J. 2011 Mar;30(3):e41-8. doi: 10.1097/INF.0b013e3182054ab9.

PMID:
21200360
23.

Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.

Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, Ginsberg R, Ciccarelli R, Corey L, Koelle DM.

Clin Vaccine Immunol. 2008 Nov;15(11):1638-43. doi: 10.1128/CVI.00167-08. Epub 2008 Sep 10.

24.

Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".

MacGregor RR, Boyer JD, Ugen KE, Tebas P, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, Weiner DB.

Vaccine. 2005 Mar 18;23(17-18):2066-73.

PMID:
15755572
25.

T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev.

MacGregor RR, Ginsberg R, Ugen KE, Baine Y, Kang CU, Tu XM, Higgins T, Weiner DB, Boyer JD.

AIDS. 2002 Nov 8;16(16):2137-43.

PMID:
12409734
26.

Magnitude and quality of antibody response to a combination hepatitis A and hepatitis B vaccine.

Abraham B, Baine Y, De-Clercq N, Tordeur E, Gerard PP, Manouvriez PL, Parenti DL.

Antiviral Res. 2002 Jan;53(1):63-73.

PMID:
11684316
27.

A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults.

Joines RW, Blatter M, Abraham B, Xie F, De Clercq N, Baine Y, Reisinger KS, Kuhnen A, Parenti DL.

Vaccine. 2001 Sep 14;19(32):4710-9.

PMID:
11535321
28.

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.

Boyer JD, Cohen AD, Vogt S, Schumann K, Nath B, Ahn L, Lacy K, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR, Weiner DB.

J Infect Dis. 2000 Feb;181(2):476-83.

PMID:
10669329
29.

Potential for plasmid DNAs as vaccines for the new millennium.

Shroff KE, Smith LR, Baine Y, Higgins TJ.

Pharm Sci Technolo Today. 1999 May;2(5):205-212.

PMID:
10322383
30.

Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial.

Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Cohen A, Nyland S, Lacy KE, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR, Weiner DB.

Clin Immunol. 1999 Jan;90(1):100-7.

PMID:
9884357
31.

DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans.

Ugen KE, Nyland SB, Boyer JD, Vidal C, Lera L, Rasheid S, Chattergoon M, Bagarazzi ML, Ciccarelli R, Higgins T, Baine Y, Ginsberg R, Macgregor RR, Weiner DB.

Vaccine. 1998 Nov;16(19):1818-21.

PMID:
9795386
32.

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB.

J Infect Dis. 1998 Jul;178(1):92-100.

PMID:
9652427
33.
34.

Novel inhibitors of the nuclear factor of activated T cells (NFAT)-mediated transcription of beta-galactosidase: potential immunosuppressive and antiinflammatory agents.

Michne WF, Schroeder JD, Guiles JW, Treasurywala AM, Weigelt CA, Stansberry MF, McAvoy E, Shah CR, Baine Y, Sawutz DG, et al.

J Med Chem. 1995 Jul 7;38(14):2557-69.

PMID:
7629796
35.

Functional characterization of novel IL-2 transcriptional inhibitors.

Baine Y, Stankunas BM, Miller P, Hobbs C, Tiberio L, Koch J, Yoon K, Sawutz D, Surowy C.

J Immunol. 1995 Apr 15;154(8):3667-77.

PMID:
7706710
36.

Expression of human interleukin-2 receptor cDNA in E. coli.

Chanda PK, Chen GF, Baine Y, Leonard WJ, Greene WC, Chang TW, Chang NT.

Biochem Biophys Res Commun. 1986 Dec 15;141(2):804-11.

PMID:
3026392
37.
38.

Cell surface phenotype of lymphoid cells from normal mice and mice treated with monoclonal anti-IgD from birth.

Skelly RR, Baine Y, Ahmed A, Xue B, Thorbecke GJ.

J Immunol. 1983 Jan;130(1):15-8.

PMID:
6600173
39.

Physiology of Igd. II. Lack of humoral immune responsiveness in lymph nodes of mice treated with anti-IgD from birth.

Baine Y, Chen YW, Jacobson EB, Pernis B, Siskind GW, Thorbecke GJ.

Eur J Immunol. 1982 Oct;12(10):882-6.

PMID:
6983443
40.

Induction and persistence of local B cell memory in mice.

Baine Y, Thorbecke GJ.

J Immunol. 1982 Feb;128(2):639-43.

PMID:
6976383
41.

Chronic suppression in mice with anti-IgD: role of B-cell numbers.

Baine Y, Chen YW, Jacobson EB, Pernis B, Siskind GW, Thorbecke GJ.

Ann N Y Acad Sci. 1982;399:360-7. No abstract available.

PMID:
6984619
42.

Effect of allotype specific anti-IgD on the immune responses of heterozygous mice.

Jacobson EB, Baine Y, Wu-Chen Y, Pernis B, Siskind GW, Thorbecke GJ.

Ann N Y Acad Sci. 1982;399:310-5. No abstract available.

PMID:
6984614
43.

Effects of allotype specific anti-IgD on the immune responses of homozygous mice.

Thorbecke GJ, Baine Y, Xue B, Chen YW, Pernis B, Siskind GW, Jacobson EB.

Ann N Y Acad Sci. 1982;399:304-9. No abstract available.

PMID:
6984613
44.

Maturity of precursor cells for germinal centers.

Thorbecke GJ, Flotte TJ, Baine Y.

Adv Exp Med Biol. 1982;149:845-7. No abstract available.

PMID:
6983242
45.

Unilateral localization of hapten-specific B memory cells in lymph node draining a footpad injection of antigen.

Baine Y, Ponzio NM, Thorbecke GJ.

Adv Exp Med Biol. 1982;149:167-78. No abstract available.

PMID:
6183930
46.
47.

Physiology of IgD. I. Compensatory phenomena in B lymphocyte activation in mice treated with anti-IgD antibodies.

Jacobson EB, Baine Y, Chen YW, Flotte T, O'Neil MJ, Pernis B, Siskind GW, Thorbecke GJ, Tonda P.

J Exp Med. 1981 Aug 1;154(2):318-32.

Supplemental Content

Support Center